In web-based survey, participants expressed concern about 'cancer spreading' or becoming invasive, not doing enough to prevent recurrence
HealthDay operates under the strictest editorial standards. Our syndicated news content is completely independent of any financial interests, is based solely on industry-respected sources and the latest scientific research, and is carefully fact-checked by a team of industry experts to ensure accuracy.
- All articles are edited and checked for factual accuracy by our Editorial Team prior to being published.
- Unless otherwise noted, all articles focusing on new research are based on studies published in peer-reviewed journals or issued from independent and respected medical associations, academic groups and governmental organizations.
- Each article includes a link or reference to the original source.
- Any known potential conflicts of interest associated with a study or source are made clear to the reader.
Please see our Editorial and Fact-Checking Policy for more detail.Editorial and Fact-Checking Policy
HealthDay Editorial Commitment
HeathDay is committed to maintaining the highest possible levels of impartial editorial standards in the content that we present on our website. All of our articles are chosen independent of any financial interests. Editors and writers make all efforts to clarify any financial ties behind the studies on which we report.
TUESDAY, Feb. 22, 2022 (HealthDay News) -- Patients with ductal carcinoma in situ (DCIS) report confusion and concern about diagnosis and treatment, according to a study published online Feb. 22 in Cancer.
Shoshana M. Rosenberg, Sc.D., M.P.H., from the Dana-Farber Cancer Institute in Boston, and colleagues administered a web-based survey in July 2014 to assess patients' perspectives about DCIS diagnosis and treatment. The analytic sample included 1,832 women (median age at diagnosis, 60 years).
The researchers identified four primary themes: uncertainty surrounding a DCIS diagnosis; uncertainty relating to treatment; concern about side effects of treatment; and concerns relating to recurrence or developing invasive breast cancer. Participants were often uncertain about whether or not they had cancer when diagnosed and about whether they should be considered a survivor. Uncertainty in relation to treatment was demonstrated as questioning the appropriateness of treatment. Concern was expressed about the "cancer spreading" or becoming invasive and that not enough was being done to prevent recurrence.
"Improved awareness of the confusion, anxiety, and uncertainty that women with DCIS may experience can inform more empathetic communication patterns," write the authors of an accompanying editorial. "Providers should seek every opportunity to understand each patient's unique experience and provide education and other forms of support to promote their overall well-being."
Several authors disclosed financial ties to the pharmaceutical and health information technology industries.
This story may be outdated. We suggest some alternatives.
The content contained in this article is over two years old. As such our recommendation is that you reference the articles below for the latest updates on this topic. This article has been left on our site as a matter of historic record. Please contact us at firstname.lastname@example.org with any questions.
Updated on May 23, 2022
Read this Next
Other Trending Articles